Beyondspring Inc是一家临床阶段的全球生物制药公司。该公司专注于开发癌症疗法,以改善未满足医疗需求的患者的临床结果。该公司的主导产品普那布林正在与多西他赛联合研究晚期非小细胞肺癌(NSCLC)的抗癌药物。普那布林是一种小分子,来源于海洋微生物中的一种天然化合物。该公司的产品普那布林是一种具有多种免疫活性的选择性免疫调节微管结合剂(SIMBA)。它可以激活免疫防御蛋白GEF-H1,导致了两种效果。一种是由于树突状细胞的成熟导致肿瘤抗原特异性 T 细胞激活以靶向癌细胞,因此具有持久的抗癌益处。另外一种通过增加造血干细胞/祖细胞 (HSPCs) 的数量,在化疗后预防化疗引起的中性粒细胞减少症 (CIN) 中的早发作用。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Lan Huang | Co-Founder, Chairman & CEO | 2014 | 55 |
| Matthew Kirkby | Independent Director | 2016 | 57 |
| Patrick Fabbio | Independent Director | 2018 | 58 |
| Jiangwen Majeti | Independent Director | 2022 | 58 |
| Douglas W. Blayney | Member of Scientific Advisors & Principal Investigators Board | - | 76 |
| Jeffrey Crawford | Member of Scientific Advisors & Principal Investigators Board | - | - |
| Yuankai Shi | Member of Scientific Advisors & Principal Investigators Board | - | - |
| David S. Ettinger | Member of Scientific Advisors & Principal Investigators Board | - | - |
| Yan Sun | Member of Scientific Advisors & Principal Investigators Board | - | - |
| Brendan P. Delaney | Independent Director | 2021 | 50 |
| Sihai Xu | Director | 2022 | 54 |